Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nortriptyline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.80 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 6/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.77 |
| ▸ | HRH1 | P35367 | 5/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.77 |
| ▸ | HTR2B | P41595 | 4/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.77 |
| ▸ | RET | P07949 | 3/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.77 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.77 |
| ▸ | HTR1A | P08908 | 3/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nortriptyline SCHEMBL41329 | 0.89 | CYP3A4 (1.00) | LMNACYP3A4SLC6A2PMP22MEN1 | |
| Nortriptyline SCHEMBL29751879 | 0.89 | CYP3A4 (1.00) | LMNACYP3A4SLC6A2PMP22MEN1 | |
| Nortriptyline SCHEMBL29362430 | 0.87 | SLC6A2 (1.00) | LMNACYP3A4SLC6A2PMP22MEN1 | |
| Nortriptyline SCHEMBL34527 | 0.87 | SLC6A2 (1.00) | LMNACYP3A4SLC6A2PMP22MEN1 | |
| Nortriptyline SCHEMBL1286980 | 0.87 | SLC6A2 (1.00) | LMNACYP3A4SLC6A2PMP22MEN1 | |
| Nortriptyline SCHEMBL7158809 | 0.86 | SLC6A2 (0.97) | LMNACYP3A4SLC6A2PMP22MEN1 | |
| Nortriptyline SCHEMBL7092935 | 0.84 | LMNA (0.94) | LMNACYP3A4SLC6A2PMP22MEN1 | |
| Nortriptyline SCHEMBL2244623 | 0.84 | SLC6A2 (0.94) | LMNACYP3A4SLC6A2PMP22MEN1 | |
| SCHEMBL30893161 | 0.79 | LMNA (0.76) | LMNACYP3A4SLC6A2PMP22MEN1 | |
| Amitriptyline SCHEMBL3897883 | 0.78 | SLC6A2 (0.81) | LMNACYP3A4SLC6A2PMP22MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118465117-B | Method and kit for specifically detecting various tricyclic antidepressants and application of kit | 山东英盛生物技术有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-118465117-A | Method and kit for specifically detecting various tricyclic antidepressants and application of kit | 山东英盛生物技术有限公司 | 2024-08-09 | — | — | CN | claimed |
| CN-117007693-A | 23 antidepressants and 17 metabolites detection method | 河南中医药大学第一附属医院 | 2023-11-07 | — | — | CN | claimed |
| EP-3977138-A1 | DETERMINATION OF ANTIDEPRESSANTS BY MASS SPECTROMETRY | Quest Diagnostics Investments LLC (US) | 2022-04-06 | — | — | EP | claimed |
| CN-114127554-A | Determination of antidepressants by mass spectrometry | 奎斯特诊断投资有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-20260072046-A1 | Rapid Method of Forensic Toxicology in Post-Mortem Individuals Using Muscle Tissue Testing | REISINGER AMY J (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250349528-A1 | DETERMINATION OF ANTIDEPRESSANTS BY MASS SPECTROMETRY | QUEST DIAGNOSTICS INVEST LLC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12394612-B2 | Determination of antidepressants by mass spectrometry | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2025-08-19 | — | — | US | disclosed |
| CN-114127554-B | Determination of antidepressants by mass spectrometry | 奎斯特诊断投资有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-118465117-B | Method and kit for specifically detecting various tricyclic antidepressants and application of kit | 山东英盛生物技术有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-118465117-A | Method and kit for specifically detecting various tricyclic antidepressants and application of kit | 山东英盛生物技术有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240120188-A1 | DETERMINATION OF ANTIDEPRESSANTS BY MASS SPECTROMETRY | QUEST DIAGNOSTICS INVEST LLC (US) | 2024-04-11 | — | — | US | disclosed |
| US-11887828-B2 | Determination of antidepressants by mass spectrometry | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2024-01-30 | — | — | US | disclosed |
| CN-117007693-A | 23 antidepressants and 17 metabolites detection method | 河南中医药大学第一附属医院 | 2023-11-07 | — | — | CN | disclosed |
| EP-3977138-A1 | DETERMINATION OF ANTIDEPRESSANTS BY MASS SPECTROMETRY | Quest Diagnostics Investments LLC (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114127554-A | Determination of antidepressants by mass spectrometry | 奎斯特诊断投资有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260072046-A1 | Rapid Method of Forensic Toxicology in Post-Mortem Individuals Using Muscle Tissue Testing | TNNC1, TPM3, TNNI3 | SLC6A2 198/4885SLC6A4 119/4885LMNA 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.